DSM-Firmenich stock edges lower as Indonesia expansion follows share buybacks

Published on 09/16/2026 at 23:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DSM-Firmenich stock trades slightly lower on September 16, 2026 after the group expanded its Indonesian footprint and reported new share buybacks. The company recently repurchased 385,000 shares at an average price of EUR 92.07, lifting total buybacks to 6.4 million shares.

Fotorealistisches Duftlabor mit Wissenschaftlern und Destillationsanlagen — dsm-firmenich AG (ISIN CH1216478797) betreibt moderne Duftlabore mit Wissenschaftlern und Analysegeräten für Aromastoffe, Illustration mit AI erstellt.

DSM-Firmenich stock (ISIN CH1216478797) is trading slightly weaker on September 16, 2026, with the shares at around 86.35 Swiss francs on the SIX Swiss Exchange, about 0.29 percent below the previous day in intraday trading.

Indonesia expansion and recent share buybacks

DSM-Firmenich, the Swiss nutrition and health ingredients group listed on Euronext Amsterdam and SIX Swiss Exchange, has highlighted its growth ambitions in Asia by expanding its presence in Indonesia in September 2026.

According to finanzen.ch on September 16, 2026, DSM-Firmenich is expanding its capacities and presence in Indonesia, including activities at its facilities in the country, underlining the strategic importance of the Southeast Asian market for its nutrition and health portfolio.

In parallel, DSM-Firmenich continues to return capital to shareholders through its ongoing share buyback program. As Globenewswire reported on September 16, 2026, DSM-Firmenich repurchased 385,000 shares between September 7, 2026 and September 11, 2026 at an average price of 92.07 euros per share, for a total amount of 35.4 million euros.

The same release states that the total number of shares repurchased under the program to date is 6,402,212 shares at an average price of 72.91 euros, corresponding to a total consideration of 466.8 million euros, giving investors a concrete sense of the scale of the buyback relative to the company’s approximately 9 billion euros of revenue from continuing operations after the divestment of Animal Nutrition & Health.

Recent trading levels and valuation context

While the intraday quote on the SIX Swiss Exchange stands around 86.35 Swiss francs on September 16, 2026, DSM-Firmenich’s listing on Euronext Amsterdam offers a complementary view of valuation in euros.

According to the overview on MarketScreener on September 16, 2026, DSM-Firmenich shares recently closed at 91.60 euros on Euronext Amsterdam, with a latest real-time indication of 91.36 euros, a move of 0.07 percent lower on the day.

The same MarketScreener snapshot shows that despite the slight daily dip, the stock has gained 32.56 percent since the beginning of the year, illustrating a strong year-to-date performance compared with its modest short-term fluctuations.

For investors tracking longer-term levels, the MarketScreener data also point to an average analyst price target of 93.62 euros, only slightly above the latest close of 91.60 euros, suggesting that the stock is trading relatively close to consensus fair value.

Fundamentals and strategic focus

DSM-Firmenich’s current financial profile reflects its reshaped portfolio after exiting Animal Nutrition & Health. As Globenewswire notes in the buyback update on September 16, 2026, DSM-Firmenich generates more than 9 billion euros of revenue from its continuing operations, providing a scale benchmark for the group in the global nutrition, health and beauty ingredients market.

The Indonesian capacity expansion described by finanzen.ch on September 16, 2026, fits into this broader strategy: increasing local production and development capabilities in fast-growing markets is intended to support revenue growth and improve supply-chain resilience.

From an investor perspective, the combination of a significant buyback program totaling 466.8 million euros and a year-to-date price increase of 32.56 percent illustrates how DSM-Firmenich is balancing shareholder returns with investment in organic growth, at a time when the stock is trading only modestly below the average analyst target of 93.62 euros.

Stock price and market data

On September 16, 2026, DSM-Firmenich stock traded at around 86.35 Swiss francs on the SIX Swiss Exchange during the morning session, roughly 0.29 percent below the prior day’s level, according to intraday data cited by finanzen.ch.

Using the Euronext Amsterdam closing price of 91.60 euros reported by MarketScreener on September 16, 2026, DSM-Firmenich’s market capitalization can be inferred in the multi-billion-euro range, consistent with the more than 9 billion euros of revenue from continuing operations referenced in the Globenewswire release.